A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

2013164 citationsJournal Articlebronze Open Access

Authors

Andrew X. Zhu · East Jefferson General Hospital

Richard S. Finn · Northwestern University

Mary F. Mulcahy · University of Pittsburgh

Jayne Gurtler · University of Pittsburgh

Weijing Sun · East Jefferson General Hospital

Jonathan D. Schwartz · University of California, Los Angeles

Rita P. Dalal

Abstract

Ramucirumab monotherapy may confer anticancer activity in advanced hepatocellular carcinoma with an acceptable safety profile. Exploratory biomarker studies showed changes in circulating VEGF, PlGF, and sVEGFR-2 that are consistent with those seen with other anti-VEGF agents.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cancer Mechanisms and Therapy Liver physiology and pathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 19, Issue 23, pp. 6614-6623

DOI: 10.1158/1078-0432.ccr-13-1442

Field-Weighted Citation Impact: 10.33